Diversity-Oriented Synthesis of Diol-Based Peptidomimetics as Potential HIV Protease Inhibitors and Antitumor Agents.
Paresh M VadhadiyaMarc-Alexandre JeanChahrazed BouzribaThomas TremblayPatrick LagüeSébastien FortinJohn BoukouvalasDenis GiguèrePublished in: Chembiochem : a European journal of chemical biology (2018)
Peptidomimetic HIV protease inhibitors are an important class of drugs used in the treatment of AIDS. The synthesis of a new type of diol-based peptidomimetics is described. Our route is flexible, uses d-glucal as an inexpensive starting material, and makes minimal use of protection/deprotection cycles. Binding affinities from molecular docking simulations suggest that these compounds are potential inhibitors of HIV protease. Moreover, the antiproliferative activities of compounds 33 a, 35 a, and 35 b on HT-29, M21, and MCF7 cancer cell lines are in the low micromolar range. The results provide a platform that could facilitate the development of medically relevant asymmetrical diol-based peptidomimetics.
Keyphrases
- antiretroviral therapy
- hiv positive
- molecular docking
- hiv infected
- hiv testing
- human immunodeficiency virus
- hiv aids
- hepatitis c virus
- men who have sex with men
- molecular dynamics simulations
- high throughput
- south africa
- papillary thyroid
- molecular dynamics
- squamous cell carcinoma
- young adults
- breast cancer cells
- combination therapy
- squamous cell
- replacement therapy